Anebulo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Richie Cunningham

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris	18.3%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Richie Cunningham's beloning veranderd ten opzichte van Anebulo Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	US$2m	US$333k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.82M ) Richie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 483.75K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richie te vergelijken met de prestaties van het bedrijf.

CEO

Richie Cunningham (53 yo)

1.1yrs

Tenure

US$1,819,383

Compensatie

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Lawler	Founder & Chairman	4.6yrs	US$83.11k	46.27% € 20.8m
Richard Cunningham	CEO & Director	1.1yrs	US$1.82m	geen gegevens
Daniel George	Principal Accounting Officer	1.2yrs	US$194.25k	geen gegevens
Kenneth Cundy	Chief Scientific Officer	2.5yrs	US$612.15k	0% € 0

1.8yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 214 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Lawler	Founder & Chairman	4.6yrs	US$83.11k	46.27% € 20.8m
Richard Cunningham	CEO & Director	1.1yrs	US$1.82m	geen gegevens
Bimal Shah	Independent Director	1.1yrs	US$124.53k	0% € 0
Kenneth Lin	Lead Independent Director	3.8yrs	US$68.24k	0% € 0
Areta Kupchyk	Independent Director	3.6yrs	US$76.87k	0% € 0
Jason Aryeh	Independent Director	3.7yrs	US$83.24k	0% € 0
Nathaniel Calloway	Independent Director	2.1yrs	US$67.26k	0% € 0
Aron English	Independent Director	4.4yrs	US$66.87k	17.95% € 8.1m
Andrew Monte	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Arjun Chanmugam	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 214 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Anebulo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Recent updates

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

Anebulo Pharmaceuticals, Inc. announced that it expects to receive $6.646748 million in funding from 22NW, LP and other investors

Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc.(NasdaqCM:ANEB) dropped from Russell Microcap Value Index

Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of A Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd